Journal Article (Letter)

DKFZ-2019-02421

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Stilgenbauer, S. ; Aurran Schleinitz, T. ; Eichhorst, B. ; Lang, F. ; Offner, F. ; Rossi, J.-F. ; Schroyens, W. ; Van Den Neste, E. ; Ysebaert, L. ; von Wangenheim, U. ; Ursula Kress, U. ; Blum, P. ; Zenz, T. (Last author)

2019
Springer Nature London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41375-019-0475-z

---

Contributing Institute(s):

1. Translationale Medizinische Onkolologie (B340)

Research Program(s):

1. 312 - Functional and structural genomics (POF3-312) (POF3-312)

Appears in the scientific report 2019

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---